A detailed history of Ifp Advisors, Inc transactions in Mirati Therapeutics, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 3,678 shares of MRTX stock, worth $0. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,678
Previous 3,678 -0.0%
Holding current value
$0
Previous $160,000 35.0%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 12, 2023

BUY
$27.8 - $45.35 $36,779 - $59,998
1,323 Added 56.18%
3,678 $160,000
Q2 2023

Aug 04, 2023

SELL
$36.13 - $49.49 $5,202 - $7,126
-144 Reduced 5.76%
2,355 $85,000
Q1 2023

Apr 18, 2023

BUY
$36.54 - $54.26 $3,507 - $5,208
96 Added 4.0%
2,499 $92,000
Q4 2022

Feb 07, 2023

BUY
$41.27 - $98.62 $10,606 - $25,345
257 Added 11.98%
2,403 $104,000
Q3 2022

Nov 08, 2022

BUY
$59.5 - $86.7 $8,627 - $12,571
145 Added 7.25%
2,146 $92,000
Q2 2022

Sep 06, 2022

BUY
$39.16 - $88.71 $78,359 - $177,508
2,001 New
2,001 $86,000
Q2 2022

Aug 12, 2022

SELL
$39.16 - $88.71 $78,359 - $177,508
-2,001 Closed
0 $0
Q1 2022

Sep 06, 2022

BUY
$75.82 - $150.97 $113,350 - $225,700
1,495 Added 295.45%
2,001 $164,000
Q1 2022

Aug 08, 2022

BUY
$75.82 - $150.97 $38,364 - $76,390
506 New
506 $41,000
Q3 2021

Oct 06, 2021

SELL
$132.13 - $177.45 $0 - $0
0 Closed
0 $0
Q2 2021

Jul 13, 2021

BUY
$144.0 - $179.73 $0 - $0
0 New
0 $0
Q1 2021

Apr 30, 2021

BUY
$158.92 - $221.61 $0 - $0
0 New
0 $0
Q4 2020

Jan 25, 2021

BUY
$162.05 - $240.27 $0 - $0
0 New
0 $0
Q3 2020

Oct 29, 2020

BUY
$113.26 - $167.27 $0 - $0
0 New
0 $0
Q2 2020

Aug 05, 2020

BUY
$72.01 - $120.39 $0 - $0
0 New
0 $0
Q1 2020

May 12, 2020

BUY
$69.78 - $116.21 $0 - $0
0 New
0 $0
Q4 2019

Jan 17, 2020

BUY
$70.76 - $128.86 $0 - $0
0 New
0 $0
Q3 2018

Oct 25, 2018

SELL
$47.1 - $62.7 $778,845 - $1.04 Million
-16,536 Closed
0 $0
Q1 2018

May 09, 2018

BUY
$17.2 - $34.95 $284,419 - $577,933
16,536 New
16,536 $0

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.